Home » Clinical Trials » Therapeutic Areas
Therapeutic Areas: Psychiatry/Psychology | Neurology
Disease Category: Schizophrenia and Schizoaffective Disorders
Location: United States, IL
A 17-week, Phase 2, Multicenter, Randomized, Double-Blind Study of Treatment with LY2140023 Combined with SOC to placebo Combined with SOC as the Treatment of Patients with DSM-IV-TR Schizophrenia with Prominent Negative Symptoms
The primary objective of this study is to determine if treatment with LY2140023
compared to placebo (an inactive substance), when added to a fixed dose of a standard of care (SOC) antipsychotic, will demonstrate significantly greater reduction of negative symptoms.
Patients included in this study will be concurrently receiving 1 of 4 current FDA approved antipsychotics: aripiprazole, olanzapine, risperidone, or quetiapine
Please contact Alexian Brothers for more information on participation.
CW ID: 176871
Date Last Changed:
July 22, 2013
Alexian Brothers Hospital Network1786 Moon Lake Boulevard, Suite 200Hoffman Estates, IL 60169Phone: 847-230-3599
Alexian Brothers Hospital Network
If you would like to learn more about participating in this research study, please email the trial contact using the form below.
We value your privacy and your information will only be used by the research center to contact
you regarding this study.
DISCLAIMER: CenterWatch does not conduct clinical research.
CenterWatch is a publishing company that posts clinical trials information on behalf of sponsor companies,
contract research organizations, clinical research sites and other interested parties. This information
is designed to help patients find clinical trials of interest and contact the research centers
conducting the trials.
Copyright © 1995-2015 CenterWatch.